Dopamine as the wind of the psychotic fire: new evidence from brain imaging studies

Abnormalities of dopamine function in schizophrenia are suggested by the common antidopaminergic properties of antipsychotic medications. However, direct evidence of a hyperdopaminergic state in schizophrenia has been diffcult to demonstrate, given the diffculty of measuring dopamine transmission in the living human brain. This situation is rapidly changing. Recent developments in positron emission tomography and single-photon emission tomographic techniques enabled measurement of acute fluctuation of synaptic dopamine in the vicinity of D2 receptors. Using this technique, we, and others, measured the increase in dopamine transmission following aute amphetamine challenge in untreated patients with schizophrenia and matched healthy subjects. Following a brief overview of these new brain imaging techniques, the main results derived with this method in patients with schizophrenia are described: (1) amphetamine-induced dopamine release is elevated in patients with schizophrenia, supporting the idea that schizophrenia is associated with dysregulation of dopamine transmission; (2) following amphetamine, hyperactivity of dopamine transmission is associated with activation of psychotic symptomatology; (3) this dysregulation of dopamine release is not a long-term consequence of previous neuroleptic treatment, and is detected in never-medicated patients experiencing a first episode of the illness; and (4) in contrast, this exaggerated response of the dopamine system to amphetamine exposure is not detected in patients studied during a period of illness stabilization, suggesting that the hyperdopaminergic state associated with schizophrenia fluctuates over time. In conclusion, a hyperdopaminergic state might be present in schizophrenia during the initial episode and subsequent relapses, but not during periods of remission. This finding has important consequences for the development of new treatment strategies for the remission phase.

[1]  A. Carlsson,et al.  EFFECT OF CHLORPROMAZINE OR HALOPERIDOL ON FORMATION OF 3METHOXYTYRAMINE AND NORMETANEPHRINE IN MOUSE BRAIN. , 2009, Acta pharmacologica et toxicologica.

[2]  M Laruelle,et al.  Stability of [123I]IBZM SPECT measurement of amphetamine‐induced striatal dopamine release in humans , 1999, Synapse.

[3]  C. Halldin,et al.  Changes in striatal D2‐receptor density following chronic treatment with amphetamine as assessed with pet in nonhuman primates , 1999, Synapse.

[4]  J S Fowler,et al.  Comparable changes in synaptic dopamine induced by methylphenidate and by cocaine in the baboon brain , 1999, Synapse.

[5]  M Laruelle,et al.  Alterations of benzodiazepine receptors in type II alcoholic subjects measured with SPECT and [123I]iomazenil. , 1998, The American journal of psychiatry.

[6]  M. Laruelle Imaging dopamine transmission in schizophrenia. A review and meta-analysis. , 1998, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.

[7]  A. Malhotra,et al.  Effects of NMDA antagonism on striatal dopamine release in healthy subjects: Application of a novel PET approach , 1998, Synapse.

[8]  J. Krystal,et al.  Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. , 1998, The American journal of psychiatry.

[9]  D. Brooks,et al.  Evidence for striatal dopamine release during a video game , 1998, Nature.

[10]  Daniel R. Weinberger,et al.  Neonatal lesions of the medial temporal lobe disrupt prefrontal cortical regulation of striatal dopamine , 1998, Nature.

[11]  Michael D. Nelson,et al.  Hippocampal volume reduction in schizophrenia as assessed by magnetic resonance imaging : A meta-analytic study , 1998 .

[12]  T. Svensson,et al.  Non‐NMDA excitatory amino acid receptors in the ventral tegmental area mediate systemic dizocilpine (MK‐801) induced hyperlocomotion and dopamine release in the nucleus accumbens , 1998, Journal of neuroscience research.

[13]  Jeffrey A Lieberman,et al.  Neurochemical Sensitization in the Pathophysiology of Schizophrenia: Deficits and Dysfunction in Neuronal Regulation and Plasticity , 1997, Neuropsychopharmacology.

[14]  Marc Laruelle,et al.  Imaging D2 Receptor Occupancy by Endogenous Dopamine in Humans , 1997, Neuropsychopharmacology.

[15]  G D Pearlson,et al.  PET study of competition between intravenous cocaine and [11C]raclopride at dopamine receptors in human subjects. , 1997, The American journal of psychiatry.

[16]  N. Bunnett,et al.  Turning off the signal: mechanisms that attenuate signaling by G protein-coupled receptors. , 1997, The American journal of physiology.

[17]  L. Seiden,et al.  Evaluation of d‐amphetamine effects on the binding of dopamine D‐2 receptor radioligand, 18F‐fallypride in nonhuman primates using positron emission tomography , 1997, Synapse.

[18]  J. Edwardson,et al.  Endocytosis and recycling of G protein-coupled receptors. , 1997, Trends in pharmacological sciences.

[19]  J. Lieberman,et al.  Relapse and rehospitalization during maintenance treatment of schizophrenia. The effects of dose reduction and family treatment. , 1997, Archives of general psychiatry.

[20]  W C Eckelman,et al.  Quantification of Amphetamine-Induced Changes in [11C]Raclopride Binding with Continuous Infusion , 1997, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[21]  Christer Halldin,et al.  Effect of reserpine‐induced depletion of synaptic dopamine on [11C]Raclopride binding to D2‐dopamine receptors in the monkey brain , 1997, Synapse.

[22]  A. Malhotra,et al.  Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[23]  C. Crouzel,et al.  Presynaptic dopaminergic function in the striatum of schizophrenic patients , 1997, Schizophrenia Research.

[24]  P B Hoffer,et al.  Microdialysis and SPECT measurements of amphetamine‐induced dopamine release in nonhuman primates , 1997, Synapse.

[25]  E. Abercrombie,et al.  Effects of MK-801 on spontaneous and amphetamine-stimulated dopamine release in striatum measured with in vivo microdialysis in awake rats , 1996, Brain Research Bulletin.

[26]  J. Krystal,et al.  Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[27]  B. Bloch,et al.  Ultrastructural localization of D1 dopamine receptor immunoreactivity in rat striatonigral neurons and its relation with dopaminergic innervation , 1996, Brain Research.

[28]  B. Moghaddam,et al.  The Prefrontal Cortex Regulates the Basal Release of Dopamine in the Limbic Striatum: An Effect Mediated by Ventral Tegmental Area , 1996, Journal of neurochemistry.

[29]  J. Hietala,et al.  Presynaptic dopamine function in striatum of neuroleptic-naive schizophrenic patients , 1995, The Lancet.

[30]  Carol A. Tamminga,et al.  Subanesthetic Doses of Ketamine Stimulate Psychosis in Schizophrenia , 1995, Neuropsychopharmacology.

[31]  J. Bolam,et al.  Electron microscopic analysis of D1 and D2 dopamine receptor proteins in the dorsal striatum and their synaptic relationships with motor corticostriatal afferents , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[32]  D. Charney,et al.  Spect imaging of striatal dopamine release after amphetamine challenge in humans: Relationship between subjective effects and dopamine release , 1995, Schizophrenia Research.

[33]  A. D. Smith,et al.  Immunocytochemical localization of D1 and D2 dopamine receptors in the basal ganglia of the rat: Light and electron microscopy , 1995, Neuroscience.

[34]  A. Grace,et al.  The tonic/phasic model of dopamine system regulation: its relevance for understanding how stimulant abuse can alter basal ganglia function. , 1995, Drug and alcohol dependence.

[35]  T. Robinson,et al.  Amphetamine‐Induced time‐dependent sensitization of dopamine neurotransmission in the dorsal and ventral striatum: A microdialysis study in behaving rats , 1995, Synapse.

[36]  J D Brodie,et al.  Serotonergic modulation of striatal dopamine measured with positron emission tomography (PET) and in vivo microdialysis , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[37]  Alan C. Evans,et al.  Elevated dopa decarboxylase activity in living brain of patients with psychosis. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[38]  P B Hoffer,et al.  In vivo quantification of dopamine D2 receptor parameters in nonhuman primates with [123I]iodobenzofuran and single photon emission computerized tomography. , 1994, European journal of pharmacology.

[39]  P S Goldman-Rakic,et al.  D1 dopamine receptor immunoreactivity in human and monkey cerebral cortex: predominant and extrasynaptic localization in dendritic spines. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[40]  A C Roberts,et al.  6-Hydroxydopamine lesions of the prefrontal cortex in monkeys enhance performance on an analog of the Wisconsin Card Sort Test: possible interactions with subcortical dopamine , 1994, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[41]  Robert B. Innis,et al.  SPECT Quantification of [123I]Iomazenil Binding to Benzodiazepine Receptors in Nonhuman Primates: II. Equilibrium Analysis of Constant Infusion Experiments and Correlation with in vitro Parameters , 1994, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[42]  Jean Logan,et al.  Imaging endogenous dopamine competition with [11C]raclopride in the human brain , 1994, Synapse.

[43]  J. Seibyl,et al.  SPECT measurement of benzodiazepine receptors in human brain with iodine-123-iomazenil: kinetic and equilibrium paradigms. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[44]  V. Lehtinen,et al.  Striatal D2 dopamine receptor characteristics in neuroleptic-naive schizophrenic patients studied with positron emission tomography. , 1994, Archives of general psychiatry.

[45]  K. Blum,et al.  No structural mutation in the dopamine D2 receptor gene in alcoholism or schizophrenia. Analysis using denaturing gradient gel electrophoresis. , 1994, JAMA.

[46]  R. Murray,et al.  D2 Dopamine Receptor Binding in the Basal Ganglia of Antipsychotic-Free Schizophrenic Patients , 1994, British Journal of Psychiatry.

[47]  R. G. Manning,et al.  Evaluation of 5‐[18F]Fluoropropylepidepride as a potential pet radioligand for imaging dopamine D2 receptors , 1993, Synapse.

[48]  D L Price,et al.  Localization of D1 and D2 dopamine receptors in brain with subtype-specific antibodies. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[49]  P. Kalivas Neurotransmitter regulation of dopamine neurons in the ventral tegmental area , 1993, Brain Research Reviews.

[50]  J S Fowler,et al.  Striatal binding of the PET ligand 11C‐raclopride is altered by drugs that modify synaptic dopamine levels , 1993, Synapse.

[51]  P B Hoffer,et al.  Single photon emission tomography measurement of benzodiazepine receptor number and affinity in primate brain: a constant infusion paradigm with [123I]iomazenil. , 1993, European journal of pharmacology.

[52]  R R MacGregor,et al.  GABAergic inhibition of endogenous dopamine release measured in vivo with 11C-raclopride and positron emission tomography , 1992, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[53]  Marc Laruelle,et al.  Amphetamine‐stimulated dopamine release competes in vivo for [123I]IBZM binding to the D2 receptor in nonhuman primates , 1992, Synapse.

[54]  K. Davis,et al.  Dopamine in schizophrenia: a review and reconceptualization. , 1991, The American journal of psychiatry.

[55]  T. Goldberg,et al.  Lack of a bimodal distribution of ventricular size in schizophrenia: A Gaussian mixture analysis of 1056 cases and controls , 1991, Biological Psychiatry.

[56]  D. Wong,et al.  Effects of endogenous dopamine on kinetics of [3H]N‐methylspiperone and [3H]raclopride binding in the rat brain , 1991, Synapse.

[57]  Jean Logan,et al.  Effects of endogenous dopamine on measures of [18F]N‐methylspiroperidol binding in the basal ganglia: Comparison of simulations and experimental results from PET studies in baboons , 1991, Synapse.

[58]  P. Kalivas,et al.  Dopamine transmission in the initiation and expression of drug- and stress-induced sensitization of motor activity , 1991, Brain Research Reviews.

[59]  J S Fowler,et al.  Amphetamine induced decreases in (18F)‐N‐methylspiroperidol binding in the baboon brain using positron emission tomography (PET) , 1991, Synapse.

[60]  S. L. Patrick,et al.  Concomitant sensitization of amphetamine-induced behavioral stimulation and in vivo dopamine release from rat caudate nucleus , 1991, Brain Research.

[61]  Svante B. Ross,et al.  Synaptic Concentration of Dopamine in the Mouse Striatum in Relationship to the Kinetic Properties of the Dopamine Receptors and Uptake Mechanism , 1991, Journal of neurochemistry.

[62]  L. Parsons,et al.  Extracellular Concentrations of Cocaine and Dopamine Are Enhanced During Chronic Cocaine Administration , 1990, Journal of neurochemistry.

[63]  S. Stone-Elander,et al.  D2 dopamine receptors in neuroleptic-naive schizophrenic patients. A positron emission tomography study with [11C]raclopride. , 1990, Archives of general psychiatry.

[64]  S. Otsuki,et al.  Enhanced extracellular dopamine level may be the fundamental neuropharmacological basis of cross-behavioral sensitization between methamphetamine and cocaine — an in vivo dialysis study in freely moving rats , 1990, Brain Research.

[65]  P. Seeman,et al.  Link between D1 and D2 dopamine receptors is reduced in schizophrenia and Huntington diseased brain. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[66]  D. Segal,et al.  Concomitant characterization of behavioral and striatal neurotransmitter response to amphetamine using in vivo microdialysis , 1989, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[67]  T. Svensson,et al.  Local cooling of pre-frontal cortex induces pacemaker-like firing of dopamine neurons in rat ventral tegmental area in vivo. , 1989, Acta physiologica Scandinavica.

[68]  S. Otsuki,et al.  Subchronic methamphetamine treatment enhances methamphetamine- or cocaine-induced dopamine efflux in vivo , 1989, Biological Psychiatry.

[69]  T. Robinson,et al.  Persistent sensitization of dopamine neurotransmission in ventral striatum (nucleus accumbens) produced by prior experience with (+)-amphetamine: a microdialysis study in freely moving rats , 1988, Brain Research.

[70]  A Carlsson,et al.  The current status of the dopamine hypothesis of schizophrenia. , 1988, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.

[71]  P. Seeman,et al.  Dopamine receptors in brain and periphery , 1987, Neurochemistry International.

[72]  P Riederer,et al.  Human brain D1 and D2 dopamine receptors in schizophrenia, Alzheimer's, Parkinson's, and Huntington's diseases. , 1987, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.

[73]  J. Lieberman,et al.  Prediction of relapse in schizophrenia. , 1987, Archives of general psychiatry.

[74]  T. Ljungberg,et al.  A direct comparison of amphetamine-induced behaviours and regional brain dopamine release in the rat using intracerebral dialysis , 1987, Brain Research.

[75]  G. Pearlson,et al.  Positron emission tomography reveals elevated D2 dopamine receptors in drug-naive schizophrenics. , 1986, Science.

[76]  A. M. Friedman,et al.  Exogenous l-dopa alters spiroperidol binding, in vivo, in the mouse striatum. , 1986, Life sciences.

[77]  T. Robinson,et al.  Enduring changes in brain and behavior produced by chronic amphetamine administration: A review and evaluation of animal models of amphetamine psychosis , 1986, Brain Research Reviews.

[78]  B. Angrist,et al.  CNS stimulants as tools in the study of schizophrenia , 1984, Trends in Neurosciences.

[79]  J. Lieberman,et al.  Methylphenidate challenge as a predictor of relapse in schizophrenia. , 1984, The American journal of psychiatry.

[80]  M. Mintun,et al.  A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography , 1984, Annals of neurology.

[81]  J. Korf,et al.  In vivo binding of N-n-propylnorapomorphine in the rat brain: regional localization, quantification in striatum and lack of correlation with dopamine metabolism. , 1983, European journal of pharmacology.

[82]  W. Bunney,et al.  d-Amphetamine-induced heterogeneous changes in psychotic behavior in schizophrenia. , 1982, The American journal of psychiatry.

[83]  D. Sibley,et al.  Anterior pituitary dopamine receptors. Demonstration of interconvertible high and low affinity states of the D-2 dopamine receptor. , 1982, The Journal of biological chemistry.

[84]  K. Fuxe,et al.  Regional in vivo binding of [3H]N-propylnorapomorphine in the mouse brain. Evidence for labelling of central dopamine receptors. , 1981, European Journal of Pharmacology.

[85]  C. Carter,et al.  Effect of lesion of cortical dopamine terminals on subcortical dopamine receptors in rats , 1980, Nature.

[86]  T. Crow,et al.  Molecular pathology of schizophrenia: more than one disease process? , 1980, British medical journal.

[87]  P. Seeman,et al.  Binding of 3H-neuroleptics and 3H-apomorphine in schizophrenic brains , 1978, Nature.

[88]  M. Poulter,et al.  INCREASED DOPAMINE-RECEPTOR SENSITIVITY IN SCHIZOPHRENIA , 1978, The Lancet.

[89]  S. Snyder,et al.  Antischizophrenic drugs: chronic treatment elevates dopamine receptor binding in brain. , 1977, Science.

[90]  S H Snyder,et al.  Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs , 1976, Science.

[91]  D. Janowsky,et al.  Methylphenidate, dextroamphetamine, and levamfetamine. Effects on schizophrenic symptoms. , 1976, Archives of general psychiatry.

[92]  P. Seeman,et al.  Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons. , 1975, Science.

[93]  S. Udenfriend,et al.  Inhibitors of purified beef adrenal tyrosine hydroxylase. , 1965, Biochemical pharmacology.

[94]  Peter Herscovitch,et al.  Comparison of Bolus and Infusion Methods for Receptor Quantitation: Application to [18F]Cyclofoxy and Positron Emission Tomography , 1993, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[95]  N. Volkow,et al.  Glutamate Modulation of Dopamine Measured in Vivo with Positron Emission Tomography (PET) and 11C-Raclopride in Normal Human Subjects , 1998, Neuropsychopharmacology.

[96]  P. Kalivas,et al.  The pharmacology and neural circuitry of sensitization to psychostimulants. , 1993, Behavioural pharmacology.

[97]  J. Lieberman,et al.  Dopaminergic mechanisms in idiopathic and drug-induced psychoses. , 1990, Schizophrenia bulletin.

[98]  P. Kalivas,et al.  Effect of acute and daily cocaine treatment on extracellular dopamine in the nucleus accumbens , 1990, Synapse.

[99]  P. Seeman,et al.  Endogenous dopamine lowers the dopamine D2 receptor density as measured by [3H]raclopride: Implications for positron emission tomography of the human brain , 1989, Synapse.

[100]  S. Kay,et al.  The positive and negative syndrome scale (PANSS) for schizophrenia. , 1987, Schizophrenia bulletin.

[101]  P. Seeman,et al.  Dopamine receptors and the dopamine hypothesis of schizophrenia , 1987, Synapse.

[102]  T. Crow,et al.  Dopamine receptor changes in schizophrenia in relation to the disease process and movement disorder. , 1983, Journal of neural transmission. Supplementum.

[103]  A. B. Hollingshead,et al.  Four factor index of social status , 1975 .

[104]  A. Sjoerdsma,et al.  BLOCKADE OF ENDOGENOUS NOREPINEPHRINE SYNTHESIS BY ALPHA-METHYL-TYROSINE, AN INHIBITOR OF TYROSINE HYDROXYLASE. , 1965, The Journal of pharmacology and experimental therapeutics.